Breakthroughs in Reducing the Risk of CV Death for Patients With CHF Education Center
This Disease Education Center is intended to share with our readers expert opinion and clinical advances in the treatment and management of congestive heart failure, in which approximately 200,000 new cases in the U.S. emerge each year.
Visit the Breakthroughs in Reducing the Risk of CV Death for Patients With CHF Video Library for the latest news from key physician opinion leaders.
ATTR-ACT Trial: Tafamidis Meglumine Reduces Cardiovascular Mortality
November 24, 2020
A clinical trial showed that a combination of tafamidis meglumine and tafamidis performed better than those receiving 20 mg of tafamidis meglumine alone for transthyretin amyloid cardiomyopathy...
AHA Issues New Statements on Heart Failure Care
December 5, 2020Two recent statements from the American Heart Association (AHA) on the treatment of heart failure looked not only at ways to better help the patient...
Study Examines High Number of Medications Prescribed to Older Heart Failure Patients
November 10, 2020As heart failure patients age, the number of medications they take can often increase, especially after a hospitalization...
Remote Management Brings Heart Failure Therapy Closer to Guidelines
November 1, 2020Bringing treatment for patients with heart failure with reduced ejection fraction (HFrEF) more into line with guidelines can be achieved without more in-person visits with a cardiologist...
Discontinuation of Digoxin Remains Risky in Heart Failure Patients
September 15, 2020For decades, clinicians have been aware that discontinuing digoxin increased the risk for worsening symptoms in patients with chronic heart failure...
FDA Grants Priority Review to Vericiguat for Heart Failure Treatment
July 27, 2020The FDA has granted priority review for vericiguat as a treatment for heart failure with reduced ejection fraction...
